Edwards Lifesciences Corp

$88.40$0.11 (+0.13%)
Last updated on --.

Edwards Lifesciences Corp price

24 Hours+0.13%+$0.11
30 days-0.06%-$0.05
60 days-2.88%-$2.590
90 days+5.33%+$4.470

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Stock ticker
EW
Company
Edwards Lifesciences Corporation
Industry
Healthcare
Category
US
Stock split / reverse split
13
Launch date
Mar 27, 2000
Listed exchange
NYSE

Financials

Q2 FY2026 Earnings
Report period: Apr 1, 2026 – Jun 30, 2026

Summary: EW reported Revenue of 1.74B (+13.63%), beating expectations; EPS of 0.78 (+16.42%), beating expectations.

Revenue (USD)Beat1.74B+13.62%1.70B+14.25%40.83M+2.40%
EPS (USD)Beat0.78+16.41%0.74+19.07%0.04+4.97%
Financial estimates
● Actual● Estimate
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
0.560.500.160.660.42
-8.20%-90.26%-75.39%+8.19%-25.00%
● EPS● YoY
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
13.49B13.27B13.70B13.32B13.87B
2.88B3.07B3.36B2.99B3.14B
21.36%23.11%24.52%22.47%22.65%
● Assets● Liabilities● Ratio
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
290.20M573.70M450.90M43.80M651.90M
-21.89%+63.07%+453.64%-84.38%+124.63%
● CFO● YoY

Shareholders

Shareholders
BLACKROCK, INC.10.19%
VANGUARD CAPITAL MANAGEMENT LLC6.52%
VANGUARD PORTFOLIO MANAGEMENT LLC4.58%
STATE STREET CORP4.54%
JPMORGAN CHASE & CO3.95%
Others70.19%
Institutions
% Owned90.75%+3.65%
Shares held525.63M+21.17M
Institutions1,375+32
% OwnedPrice
Name% OwnedChange
BLACKROCK, INC.10.19%+6.20M
VANGUARD CAPITAL MANAGEMENT LLC6.52%-111.84K
VANGUARD PORTFOLIO MANAGEMENT LLC4.58%+4.38K
STATE STREET CORP4.54%+25.54K
JPMORGAN CHASE & CO3.95%+1.04M

Dividends

Stock splits
Launch date: Mar 27, 2000
DateRatio
Jun 1, 20201 → 3
Dec 14, 20151 → 2
May 28, 20101 → 2

Edwards Lifesciences Corp conversion tables

EWEW
USDUSD
0.5 EW44.2 USD
1 EW88.4 USD
5 EW442 USD
10 EW884 USD
USDUSD
EWEW
0.5 USD0.0056561 EW
1 USD0.011312 EW
5 USD0.056561 EW
10 USD0.11312 EW

More to explore

FAQ

EW is trading at $88.40, +0.13% over the last 24 hours. Track live moves on the price chart at the top of this page.

The EW stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. EW is currently trading at $88.40, +0.13% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on EW price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.

P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. EW's P/E ratio is currently 50.45 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from EW; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against EW's historical range and other companies in the Healthcare sector.

Edwards Lifesciences Corporation's market cap is currently 50.6B USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.